Changes to the rules governing the funding of CT and MRI scans by the National Health Fund – statement from the Management Board

In response to enquiries from the Company’s stakeholders and following the entry into force of Order No. 34/2026/DSOZ of the President of the National Health Fund (‘the Order’), the Management Board of VOXEL S.A. hereby announces that it is analysing the Order’s potential impact on the Group’s operations.

In accordance with the National Health Fund (NFZ) Order, the method of funding computed tomography (‘CT’) and magnetic resonance imaging (‘MRI’) scans carried out in excess of the limits specified in the contracts concluded with the NFZ has changed. From 1 April 2026, these services will be funded at 50 per cent of the potential revenue, excluding examinations carried out on children and young people up to the age of 18 and on cancer patients holding a DILO card. At the same time, CT and MRI examinations carried out in excess of the limits in the first quarter of 2026 will be reimbursed in full by the NFZ.

The VOXEL Capital Group is characterised by a diversified revenue structure, which ensures greater resilience to changes in the regulatory environment. The Management Board is analysing the impact of the aforementioned Order on the diagnostic imaging segment; however, a detailed assessment will only be possible after the first few months of its implementation, based on operational data from individual centres. We would like to point out here that in January and February 2026, CT and MRI scans performed in excess of the limits set out in the contracts with the National Health Fund (NFZ) accounted for approximately 20 per cent of the total revenue of the diagnostics segment.

In view of the above, in order to bring the VOXEL Group’s operations into line with the changes introduced, the Management Board of VOXEL S.A. will take the following measures:

–        the expansion of the range of tests not reimbursed by the National Health Fund as a key element in strengthening revenue diversification,

–         optimisation of excess production volumes,

–         reducing the labour costs of medical staff, including cutting back on costly weekend and evening shifts, conducting an in-depth analysis of test volumes and cost structures in each laboratory, and placing greater emphasis on the use of AI tools to support the analysis of tests carried out and operational processes.

The Management Board of VOXEL S.A. will keep stakeholders informed of the results of its analyses and the actions taken in separate announcements, in particular in the Company’s periodic reports.

The Management Board of VOXEL S.A.